Suchergebnisse - "Lin, Wan Hsin"

PubPharm (39)

1

A Syx-RhoA-Dia1 signaling axis regulates cell cycle progression, DNA damage, and therapy resistance in glioblastoma

enthalten in: bioRxiv.org | 2024

von Lin, W. | Feathers, R. | Cooper, L. | +3

2

A Syx-RhoA-Dia1 signaling axis regulates cell cycle progression, DNA damage, and therapy resistance in glioblastoma

enthalten in: JCI insight | 2023

von Lin, W. | Feathers, R. | Cooper, L. | +4

3

Epigenomics may begin to explain in vitro differential response to hypomethylating agents in MMR-D hypermethylated endometrial cancer

enthalten in: Epigenomics | 2023

von El Khoury, L. | Lin, W. | Smadbeck, J. | +23

4

CIViCdb 2022 : evolution of an open-access cancer variant interpretation knowledgebase

enthalten in: Nucleic acids research | 2023

von Krysiak, K. | Danos, A. | Saliba, J. | +62

5

Cadherins and catenins in cancer : connecting cancer pathways and tumor microenvironment

enthalten in: Frontiers in cell and developmental biology | 2023

von Lin, W. | Cooper, L. | Anastasiadis, P.

6

Evolution of the open-access CIViC knowledgebase is driven by the needs of the cancer variant interpretation community

enthalten in: bioRxiv.org | 2022

von Krysiak, K. | Danos, A. | Kiwala, S. | +49

7

Characterization and computational simulation of human Syx, a RhoGEF implicated in glioblastoma

enthalten in: bioRxiv.org | 2022

von Boyd, R. | Olson, T. | Zook, J. | +8

8

Characterization and computational simulation of human Syx, a RhoGEF implicated in glioblastoma

enthalten in: FASEB journal : official publication of the Federation of American Societies for Experimental Biology | 2022

von Boyd, R. | Olson, T. | Zook, J. | +8

9

Standardized evidence-based approach for assessment of oncogenic and clinical significance of NTRK fusions

enthalten in: Cancer genetics | 2022

von Saliba, J. | Church, A. | Rao, S. | +13

10

A community approach to the cancer-variant-interpretation bottleneck

enthalten in: Nature cancer | 2022

von Krysiak, K. | Danos, A. | Kiwala, S. | +49